Disponible en / Available in: Español
Nature journal announces award to research team that discovered Kaftrium for changing the lives of people with Cystic Fibrosis.
A medicine that improves quality of life
The research team that developed this treatment, consisting of Paul Negulescu, Sabine Hadida and Fredrick Van Goor of Vertex Pharmaceuticals in San Diego, are among the winners of five prestigious awards in life sciences, physics and mathematics.
As we already know, this drug has marked a turning point in the lives of people with Cystic Fibrosis who have at least one F508del mutation, approximately 70% of the group.
Mobilisation of the collective to get Kaftrio
Since this drug was approved by the European Medicines Agency, the Spanish Cystic Fibrosis Federation, all the federated associations and the Spanish Cystic Fibrosis Foundation have mobilised to put pressure on the Ministry of Health and the laboratory Vertex Pharmaceuticals.
Finally, on 8 November 2021, the Ministry of Health and the laboratory Vertex Pharmaceuticals reached a price agreement for the drug Kaftrio. In April 2022, it was approved for administration in the Balearic Islands.
New clinical trials with Kaftrio
People who do not have this mutation do not have a drug as potent as Kaftrio to treat them. However, a clinical trial with Kaftrio is underway for people with mutations other than F508del, opening up hope for the 30% of the population who cannot currently benefit from it.